Kintara Therapeutics Performance
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Kintara Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Kintara Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Kintara Therapeutics is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
Fifty Two Week Low | 0.3800 | |
Fifty Two Week High | 1.9500 |
Kintara |
Kintara Therapeutics Relative Risk vs. Return Landscape
If you would invest (100.00) in Kintara Therapeutics on January 26, 2024 and sell it today you would earn a total of 100.00 from holding Kintara Therapeutics or generate -100.0% return on investment over 90 days. Kintara Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Kintara, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Kintara Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kintara Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kintara Therapeutics, and traders can use it to determine the average amount a Kintara Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
DMPI |
Based on monthly moving average Kintara Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kintara Therapeutics by adding Kintara Therapeutics to a well-diversified portfolio.
Kintara Therapeutics Fundamentals Growth
Kintara Stock prices reflect investors' perceptions of the future prospects and financial health of Kintara Therapeutics, and Kintara Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kintara Stock performance.
Return On Equity | -316.72 | |||
Return On Asset | -136.86 | |||
Current Valuation | 13.09 M | |||
Shares Outstanding | 11.46 M | |||
Price To Earning | (1.68) X | |||
Price To Book | 3.26 X | |||
EBITDA | (8.26 M) | |||
Cash And Equivalents | 4.97 M | |||
Cash Per Share | 0.44 X | |||
Debt To Equity | (2.98) % | |||
Book Value Per Share | (0.09) X | |||
Cash Flow From Operations | (7.16 M) | |||
Earnings Per Share | (0.95) X | |||
Total Asset | 5.05 M | |||
Retained Earnings | (58.82 M) | |||
Current Asset | 5.01 M | |||
Current Liabilities | 482 K | |||
Things to note about Kintara Therapeutics performance evaluation
Checking the ongoing alerts about Kintara Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kintara Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Kintara Therapeutics is not yet fully synchronised with the market data | |
Kintara Therapeutics has some characteristics of a very speculative penny stock | |
Kintara Therapeutics has a very high chance of going through financial distress in the upcoming years | |
Net Loss for the year was (7.9 M). | |
Kintara Therapeutics currently holds about 4.97 M in cash with (7.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44. |
- Analyzing Kintara Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kintara Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Kintara Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kintara Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kintara Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kintara Therapeutics' stock. These opinions can provide insight into Kintara Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in Kintara Stock
If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |